Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

Similar articles for PubMed (Select 21990413)


Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF.

J Clin Oncol. 2011 Nov 10;29(32):4273-8. doi: 10.1200/JCO.2010.31.2835. Epub 2011 Oct 11.


Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer.

Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Fu P, Honda Y, Iyama K, Iwase H.

Mod Pathol. 2013 Jan;26(1):79-86. doi: 10.1038/modpathol.2012.151. Epub 2012 Aug 24.


Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J, Schaper C, Cuzick J.

J Clin Oncol. 2013 Aug 1;31(22):2783-90. doi: 10.1200/JCO.2012.46.1558. Epub 2013 Jul 1.


Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.

Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M.

Lancet Oncol. 2013 Oct;14(11):1067-76. doi: 10.1016/S1470-2045(13)70387-5. Epub 2013 Sep 12.


Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.

Breast Cancer Res. 2008;10(2):R30. doi: 10.1186/bcr1989. Epub 2008 Apr 1.


Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?

Milburn M, Rosman M, Mylander C, Tafra L.

Breast J. 2013 Jul-Aug;19(4):357-64. doi: 10.1111/tbj.12126. Epub 2013 May 23.


Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.

Barton S, Zabaglo L, A'Hern R, Turner N, Ferguson T, O'Neill S, Hills M, Smith I, Dowsett M.

Br J Cancer. 2012 May 22;106(11):1760-5. doi: 10.1038/bjc.2012.166. Epub 2012 Apr 24.


Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer.

Yorozuya K, Takeuchi T, Yoshida M, Mouri Y, Kousaka J, Fujii K, Nakano S, Fukutomi T, Hara K, Ichihara S, Lin Y, Kikuchi S.

J Cancer Res Clin Oncol. 2010 Jun;136(6):939-44. doi: 10.1007/s00432-009-0736-8. Epub 2009 Nov 28.


Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.

Afentakis M, Dowsett M, Sestak I, Salter J, Howell T, Buzdar A, Forbes J, Cuzick J.

Breast Cancer Res Treat. 2013 Jul;140(2):253-62. doi: 10.1007/s10549-013-2628-5. Epub 2013 Jul 13.


Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.

Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN.

Clin Cancer Res. 2005 May 1;11(9):3315-9.


Factors predicting late recurrence for estrogen receptor-positive breast cancer.

Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, Cuzick J.

J Natl Cancer Inst. 2013 Oct 2;105(19):1504-11. doi: 10.1093/jnci/djt244. Epub 2013 Sep 12.


Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.

Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, Crager M, Mamounas EP, Shak S, Wolmark N.

J Clin Oncol. 2011 Nov 20;29(33):4365-72. doi: 10.1200/JCO.2011.35.3714. Epub 2011 Oct 17.


Factors predictive of response to hormone therapy in breast cancer.

Rastelli F, Crispino S.

Tumori. 2008 May-Jun;94(3):370-83. Review.


Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.


Predicting OncoDx recurrence scores with immunohistochemical markers.

Bradshaw SH, Pidutti D, Gravel DH, Song X, Marginean EC, Robertson SJ.

Appl Immunohistochem Mol Morphol. 2013 Dec;21(6):490-6. doi: 10.1097/PAI.0b013e3182810b8e.


Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancers.

Park YH, Im SA, Cho EY, Ahn JH, Woo SY, Kim S, Keam B, Lee JE, Han W, Nam SJ, Park IA, Noh DY, Yang JH, Ahn JS, Im YH.

Oncology. 2014;86(5-6):279-88. doi: 10.1159/000362281. Epub 2014 Jun 4.


Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray.

Choi DH, Kim S, Rimm DL, Carter D, Haffty BG.

Cancer J. 2005 Sep-Oct;11(5):404-11.


Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.

Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A.

J Clin Oncol. 2008 Mar 1;26(7):1059-65. doi: 10.1200/JCO.2007.12.9437. Epub 2008 Jan 28.


Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.

Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J; Danish Breast Cancer Cooperative Group.

J Clin Oncol. 2008 Mar 20;26(9):1419-26. doi: 10.1200/JCO.2007.14.5565. Epub 2008 Feb 19.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk